Skip to Main Content

Paper Details

In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2.
Leukemia
11
2022
Author NameAffiliation
Giulia BianconDepartment of Internal Medicine and Yale Comprehensive Cancer Center, Yale University School of Medicine
Ranjini K SundaramYale University
Toma TebaldiDepartment of Internal Medicine and Yale Comprehensive Cancer Center, Yale University School of Medicine
Toma TebaldiUniversity of Trento
Ranjit S BindraYale University
Ranjit S BindraYale University
Stephanie HaleneDepartment of Internal Medicine and Yale Comprehensive Cancer Center, Yale University School of Medicine
Stephanie HaleneYale University
Stephanie HaleneYale Stem Cell Center and Yale Center for RNA Science and Medicine, Yale University School of Medicine
  • 1 - 9

Datasets

Release 1.2